嵌合抗原受体T细胞疗法的主要不良事件:表现、诊断与复苏
本文为临床综述,面向急诊科与重症医学科医生,总结嵌合抗原受体T细胞(CAR-T)疗法相关的主要不良事件。CAR-T是FDA批准用于白血病、淋巴瘤和骨髓瘤等血液恶性肿瘤的首个基因修饰细胞疗法,其副作用谱不同于传统化疗,以免疫介导的临床表现为主,尤其是细胞因子释放综合征、免疫效应细胞相关神经毒性综合征以及新近描述的免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征。这些综合征可表现为非特异性症状和体征,需与脓毒症、脑膜炎等其他危及生命的疾病鉴别。目前针对急诊医生和工作人员识别与处理CAR-T并发症的指南有限,本文提供成人及儿科CAR-T治疗患者常见与少见毒性的症状学、诊断思路和并发症处理基本原则。
要点
- CAR-T疗法相关主要不良事件包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征,可表现为非特异性症状和体征。
- 上述综合征需与脓毒症、脑膜炎等其他危及生命的疾病进行鉴别。
- CAR-T是FDA批准用于白血病、淋巴瘤和骨髓瘤等血液恶性肿瘤的首个基因修饰细胞疗法,其副作用谱不同于传统化疗。
- 目前针对急诊医生和工作人员识别与处理CAR-T并发症的指南有限,成人及儿科患者均适用。
- 本文为临床综述,提供CAR-T常见与少见毒性的症状学、诊断思路及并发症处理基本原则。
适用人群与场景
- 接受CAR-T治疗的成人及儿科患者,因CAR-T相关不良事件就诊于急诊科或重症医学科。
- CAR-T疗法获批用于白血病、淋巴瘤和骨髓瘤等血液恶性肿瘤。
红旗征与不能漏的情况
- 细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征可表现为非特异性症状和体征,需与脓毒症、脑膜炎等其他危及生命的疾病鉴别。
研究设计与关键结果
- 本文为临床综述,总结CAR-T治疗后常见与少见毒性的症状学、诊断思路及并发症处理基本原则,覆盖成人及儿科患者。
证据类型、等级与局限
- 证据类型:临床综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊科应准备诊断和处理CAR-T给药后独特的不良事件。
- 急诊医生和工作人员识别与处理CAR-T并发症的指南有限,本文提供症状学、诊断思路及并发症处理基本原则供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
With continued advances in targeted cancer treatment, such as chimeric antigen receptor T-cell (CAR-T) therapy, emergency departments (EDs) across the United States should be prepared to diagnose and care for patients who experience unique adverse events related to CAR-T administration. CAR-T therapy is the first genetically modified cellular therapy approved by the Food and Drug Administration for treatment of several hematologic malignancies, including leukemia, lymphoma, and myeloma. The side effect profile differs from conventional chemotherapy and consists of a spectrum of immune-mediated clinical manifestations, particularly cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and the more recently described immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome can present with nonspecific symptoms and signs and should be differentiated from other life-threatening pathologies such as sepsis and meningitis. There is limited guidance for emergency physicians and staff regarding the recognition and management of CAR-T complications, both in adult and pediatric patient care settings. This clinical review provides insight into the common and less common CAR-T toxicities, including symptomatology, diagnostic approach, and fundamental principles of complication management in adult and pediatric patients undergoing CAR-T therapy.
参考来源
- Dimitrov K, Merkle F, Dimitrov M, et al. Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation. Ann Emerg Med. 2025. PMID: 40817894. doi:10.1016/j.annemergmed.2025.07.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。